{
  "@context": {
    "bioagents": "https://bio.agents/ontology/",
    "bsc": "http://bioschemas.org/",
    "bsct": "http://bioschemas.org/types/",
    "dct": "http://purl.org/dc/terms/",
    "edam": "http://edamontology.org/",
    "owl": "http://www.w3.org/2002/07/owl#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://doi.org/10.1101/2021.01.20.427493",
      "@type": "sc:CreativeWork"
    },
    {
      "@id": "https://bio.agents/freddie",
      "@type": "sc:SoftwareApplication",
      "dct:conformsTo": "https://bioschemas.org/profiles/ComputationalAgent/0.6-DRAFT",
      "sc:additionalType": "Command-line agent",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_3170"
        },
        {
          "@id": "edam:topic_3512"
        },
        {
          "@id": "edam:topic_3308"
        },
        {
          "@id": "edam:topic_3320"
        }
      ],
      "sc:citation": {
        "@id": "https://doi.org/10.1101/2021.01.20.427493"
      },
      "sc:description": "Annotation-independent Detection and Discovery of Transcriptomic Alternative Splicing Isoforms.\n\nAlternative splicing (AS) is an important mechanism in the development of many cancers, as novel or aberrant AS patterns play an important role as an independent onco-driver. In addition, cancer-specific AS is potentially an effective target of personalized cancer therapeutics. However, detecting AS events remains a challenging task, especially if these AS events are not pre-annotated.",
      "sc:featureList": [
        {
          "@id": "edam:operation_0264"
        },
        {
          "@id": "edam:operation_0232"
        },
        {
          "@id": "edam:operation_3198"
        }
      ],
      "sc:name": "Freddie",
      "sc:url": "https://github.com/vpc-ccg/freddie/"
    }
  ]
}